KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Cash from Financing Activities (2017 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Cash from Financing Activities for 18 consecutive years, with $15.7 million as the latest value for Q1 2026.

  • For Q1 2026, Cash from Financing Activities fell 65.9% year-over-year to $15.7 million; the TTM value through Mar 2026 reached -$335.6 million, down 207.78%, while the annual FY2025 figure was -$305.2 million, 203.75% down from the prior year.
  • Cash from Financing Activities hit $15.7 million in Q1 2026 for Alnylam Pharmaceuticals, down from $45.3 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $297.0 million in Q3 2022 and bottomed at -$448.3 million in Q3 2025.
  • Average Cash from Financing Activities over 5 years is $35.4 million, with a median of $45.3 million recorded in 2025.
  • Year-over-year, Cash from Financing Activities skyrocketed 210.08% in 2024 and then tumbled 536.33% in 2025.
  • Alnylam Pharmaceuticals' Cash from Financing Activities stood at $63.4 million in 2022, then tumbled by 38.16% to $39.2 million in 2023, then dropped by 20.98% to $31.0 million in 2024, then surged by 46.2% to $45.3 million in 2025, then tumbled by 65.32% to $15.7 million in 2026.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $15.7 million, $45.3 million, and -$448.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.